^
BIOMARKER:

BRAF V600K

i
Other names: BRAF, B-raf proto-oncogene, B-raf proto-oncogene, Serine/threonine kinase, V-Raf murine sarcoma viral oncogene homolog B, Serine/threonine-protein kinase B-Raf, Proto-oncogene B-Raf, BRAF1, RAFB1, B-raf proto-oncogene Serine/threonine-protein kinase, Murine sarcoma viral (V-Raf) oncogene homolog B1, B-raf serine/threonine-protein, 94 KDa B-raf protein, B-RAF1
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
Related biomarkers:
Phase 1
National Cancer Institute (NCI)
Suspended
Last update posted :
09/19/2022
Initiation :
11/09/2020
Primary completion :
09/30/2022
Completion :
09/30/2022
BRAF • KRAS • ALK • ROS1 • KEAP1 • NFE2L2
|
BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • BRAF V600K • KEAP1 mutation • NFE2L2 mutation
|
sapanisertib (CB-228) • telaglenastat (CB-839) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 3
Pfizer
Recruiting
Last update posted :
09/14/2022
Initiation :
01/15/2021
Primary completion :
09/30/2024
Completion :
02/09/2030
BRAF
|
BRAF V600E • BRAF V600 • BRAF V600K
|
Keytruda (pembrolizumab) • Braftovi (encorafenib) • Mektovi (binimetinib) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1
Kari Kendra
Active, not recruiting
Last update posted :
09/09/2022
Initiation :
08/22/2014
Primary completion :
04/08/2018
Completion :
12/31/2022
BRAF • IL2
|
BRAF V600E • BRAF V600 • BRAF V600K
|
Xpovio (selinexor)
Phase 1/2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
08/19/2022
Initiation :
10/25/2013
Primary completion :
12/31/2022
Completion :
12/31/2022
BCL2
|
BRAF V600E • BRAF V600 • BRAF V600K
|
Mekinist (trametinib) • Tafinlar (dabrafenib) • navitoclax (ABT 263)
Phase 1
Pfizer
Active, not recruiting
Last update posted :
08/15/2022
Initiation :
01/02/2018
Primary completion :
07/11/2022
Completion :
03/09/2023
BRAF
|
BRAF V600E • BRAF V600K
|
Braftovi (encorafenib) • Mektovi (binimetinib) • modafinil • Invega Sustenna (paliperidone palmitate extended-release 1-month injection) • bupropion • dextromethorphan • lonigutamab (VB421) • losartan • omeprazole • rosuvastatin
Phase 1
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
08/12/2022
Initiation :
08/29/2013
Primary completion :
07/01/2023
Completion :
07/01/2023
HER-2
|
BRAF V600E • BRAF V600 • BRAF V600K
|
Tafinlar (dabrafenib) • lapatinib
Phase 3
Pfizer
Active, not recruiting
Last update posted :
08/01/2022
Initiation :
12/13/2013
Primary completion :
11/09/2016
Completion :
04/30/2023
BRAF
|
BRAF V600E • BRAF V600 • BRAF V600K
|
Zelboraf (vemurafenib) • Braftovi (encorafenib) • Mektovi (binimetinib)
Phase 2
UNICANCER
Not yet recruiting
Last update posted :
07/26/2022
Initiation :
09/15/2022
Primary completion :
04/15/2025
Completion :
04/15/2029
BRAF
|
BRAF V600E • BRAF V600 • BRAF V600K
|
Keytruda (pembrolizumab) • Braftovi (encorafenib) • Mektovi (binimetinib) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection) • lonigutamab (VB421)
Phase 3
Pierre Fabre Medicament
Recruiting
Last update posted :
07/08/2022
Initiation :
05/02/2022
Primary completion :
03/31/2027
Completion :
05/02/2035
BRAF
|
BRAF V600E • BRAF V600 • BRAF V600K
|
Braftovi (encorafenib) • Mektovi (binimetinib) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1/2
Deciphera Pharmaceuticals LLC
Recruiting
Last update posted :
05/30/2022
Initiation :
06/15/2021
Primary completion :
04/01/2024
Completion :
10/01/2024
BRAF • KRAS • NRAS • NF1
|
BRAF V600E • KRAS mutation • NRAS mutation • BRAF V600 • KRAS G12C • BRAF V600K • NF1 mutation • KRAS G12
|
Mekinist (trametinib) • Mektovi (binimetinib) • Lumakras (sotorasib) • DCC-3116 • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1b
Pfizer
Recruiting
Last update posted :
05/27/2022
Initiation :
08/03/2020
Primary completion :
03/20/2023
Completion :
09/05/2025
BRAF
|
BRAF V600E • BRAF V600 • BRAF V600K
|
Braftovi (encorafenib) • Mektovi (binimetinib) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection) • lonigutamab (VB421)
Phase 1/2
Richard Wu
Recruiting
Last update posted :
04/25/2022
Initiation :
05/31/2022
Primary completion :
12/31/2024
Completion :
12/31/2025
BRAF
|
BRAF V600E • BRAF V600 • BRAF V600K
|
Keytruda (pembrolizumab) • cyclophosphamide • fludarabine IV • Contego (lifileucel) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
Shanghai Kechow Pharma, Inc.
Recruiting
Last update posted :
04/18/2022
Initiation :
09/06/2021
Primary completion :
09/30/2024
Completion :
12/31/2024
BRAF
|
BRAF V600E • BRAF V600 • BRAF V600K
|
Zelboraf (vemurafenib) • HL-085 • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
Fondazione Melanoma Onlus
Recruiting
Last update posted :
04/13/2022
Initiation :
10/12/2020
Primary completion :
12/01/2022
Completion :
06/01/2027
TMB • CCR5
|
BRAF V600E • BRAF V600 • BRAF V600K
|
Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • Cotellic (cobimetinib) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1/2
Sumitomo Pharma Oncology, Inc.
Completed
Last update posted :
04/05/2022
Initiation :
04/01/2011
Primary completion :
06/01/2021
Completion :
06/01/2021
BRAF • ALK • ER • PGR
|
HER-2 positive • BRAF V600E • BRAF V600 • HER-2 negative • ALK positive • BRAF V600K • BRAF wild-type • ER negative • EGFR positive • PGR negative
|
paclitaxel • albumin-bound paclitaxel • napabucasin (BBI608)
Phase 1
Dana-Farber Cancer Institute
Active, not recruiting
Last update posted :
04/04/2022
Initiation :
08/31/2017
Primary completion :
02/28/2023
Completion :
08/31/2024
BRAF
|
BRAF V600E • BRAF V600 • BRAF V600K
|
Keytruda (pembrolizumab) • trebananib (AMG 386) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
Dr. Ronnie Shapira
Not yet recruiting
Last update posted :
04/01/2022
Initiation :
06/01/2022
Primary completion :
06/01/2026
Completion :
06/01/2027
MYC • CD8 • CTLA4 • ACAT1
|
BRAF V600E • BRAF V600 • BRAF V600K
|
Keytruda (pembrolizumab) • Braftovi (encorafenib) • Mektovi (binimetinib) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1/2
Jason J. Luke, MD
Recruiting
Last update posted :
03/28/2022
Initiation :
05/28/2021
Primary completion :
02/01/2025
Completion :
08/01/2027
BRAF
|
BRAF V600E • BRAF V600 • BRAF V600K • LDH elevation
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • Braftovi (encorafenib) • Mektovi (binimetinib) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
Grupo Español Multidisciplinar de Melanoma
Recruiting
Last update posted :
02/17/2022
Initiation :
07/18/2019
Primary completion :
06/01/2022
Completion :
11/01/2023
BRAF
|
BRAF V600E • BRAF V600 • BRAF V600K
|
Braftovi (encorafenib) • Mektovi (binimetinib) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection) • lonigutamab (VB421)
Phase 2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
01/28/2022
Initiation :
07/22/2014
Primary completion :
12/31/2022
Completion :
12/31/2022
ALB
|
BRAF V600E • BRAF V600 • BRAF V600K
|
Mekinist (trametinib) • Tafinlar (dabrafenib)
Phase 1/2
Abramson Cancer Center of the University of Pen...
Completed
Last update posted :
01/20/2022
Initiation :
10/01/2014
Primary completion :
10/01/2021
Completion :
10/01/2021
IL2
|
BRAF V600E • BRAF V600 • BRAF V600K • BRAF V600R • BRAF V600D
|
Mekinist (trametinib) • Tafinlar (dabrafenib) • hydroxychloroquine
Phase 2
ECOG-ACRIN Cancer Research Group
Active, not recruiting
Last update posted :
01/14/2022
Initiation :
10/23/2020
Primary completion :
09/30/2022
Completion :
09/30/2022
IL2
|
BRAF V600E • BRAF V600 • BRAF V600K
|
Mekinist (trametinib) • Tafinlar (dabrafenib) • hydroxychloroquine • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
12/22/2021
Initiation :
08/28/2013
Primary completion :
07/17/2020
ALB
|
BRAF V600E • BRAF V600 • BRAF V600K
|
Opdivo (nivolumab) • Mekinist (trametinib) • Tafinlar (dabrafenib) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar)
Phase 2/3
The Christie NHS Foundation Trust
Recruiting
Last update posted :
11/18/2021
Initiation :
11/08/2021
Primary completion :
10/01/2030
Completion :
10/01/2030
BRAF • NRAS
|
BRAF V600E • BRAF V600 • BRAF V600K • NRAS Q61K • NRAS Q61R • NRAS G12D • NRAS G12 • NRAS Q61 • NRAS Q61L • BRAF V600R
|
Opdivo (nivolumab) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
CCTU- Cancer Theme
Not yet recruiting
Last update posted :
10/28/2021
Initiation :
01/01/2022
Primary completion :
09/01/2023
Completion :
01/31/2024
BRAF
|
BRAF V600E • BRAF V600 • BRAF V600K
|
Braftovi (encorafenib) • Mektovi (binimetinib) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection) • lonigutamab (VB421)
Phase 2
University Health Network, Toronto
Recruiting
Last update posted :
09/30/2021
Initiation :
06/07/2019
Primary completion :
12/01/2023
Completion :
12/01/2023
BRAF • KIAA1549
|
BRAF V600E • BRAF mutation • BRAF V600K • BRAF fusion • BRAF V600R • BRAF V600M • BRAF T599 • BRAF V600D • BRAF V600_K601delinsE • BRAF K601
|
Braftovi (encorafenib) • Mektovi (binimetinib) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1
Pierre Fabre Medicament
Not yet recruiting
Last update posted :
09/15/2021
Initiation :
10/30/2021
Primary completion :
03/01/2024
Completion :
04/01/2024
BRAF
|
BRAF V600E • BRAF V600 • BRAF V600K
|
Braftovi (encorafenib) • Mektovi (binimetinib) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
European Organisation for Research and Treatmen...
Recruiting
Last update posted :
04/21/2021
Initiation :
10/30/2018
Primary completion :
04/01/2022
Completion :
02/01/2024
BRAF
|
BRAF V600E • BRAF V600 • BRAF V600K
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • Braftovi (encorafenib) • Mektovi (binimetinib) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
M.D. Anderson Cancer Center
Recruiting
Last update posted :
01/15/2021
Initiation :
10/22/2014
Primary completion :
10/31/2022
Completion :
10/31/2022
ALB
|
BRAF V600E • BRAF V600K
|
Mekinist (trametinib) • Tafinlar (dabrafenib)
Phase 2
UNC Lineberger Comprehensive Cancer Center
Completed
Last update posted :
11/23/2020
Initiation :
04/04/2013
Primary completion :
11/03/2017
Completion :
09/17/2020
PTEN • MAP3K8
|
BRAF V600E • BRAF mutation • BRAF V600 • BRAF V600K
|
Mekinist (trametinib) • Tafinlar (dabrafenib)
Phase 1/2
University of California, San Francisco
Completed
Last update posted :
08/17/2020
Initiation :
06/09/2012
Primary completion :
12/13/2013
Completion :
03/21/2017
PTEN
|
BRAF V600E • BRAF V600 • BRAF V600K • PTEN expression
|
Zelboraf (vemurafenib) • buparlisib (AN2025)
Phase 2
Radboud University
Recruiting
Last update posted :
06/05/2020
Initiation :
01/27/2017
Primary completion :
10/01/2022
Completion :
10/01/2023
PD-L1 • PD-1
|
BRAF V600E • BRAF V600 • BRAF V600K
|
Opdivo (nivolumab) • Zelboraf (vemurafenib) • Yervoy (ipilimumab) • Cotellic (cobimetinib) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1
Memorial Sloan Kettering Cancer Center
Completed
Last update posted :
01/22/2020
Initiation :
05/16/2017
Primary completion :
01/10/2020
Completion :
01/10/2020
BRAF
|
BRAF V600E • BRAF V600 • BRAF V600K
|
Invega Sustenna (paliperidone palmitate extended-release 1-month injection) • PF-06688992
Phase 1/2
William Grosh, MD
Withdrawn
Last update posted :
07/12/2019
Initiation :
10/29/2018
Primary completion :
10/01/2023
Completion :
10/01/2023
BRAF • IL2
|
BRAF V600E • BRAF V600 • BRAF V600K • BRAF V600R
|
Keytruda (pembrolizumab) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
Southwest Oncology Group
Recruiting
Last update posted :
12/22/2017
Initiation :
07/01/2014
Primary completion :
10/01/2017
Completion :
07/01/2021
CD4
|
BRAF V600E • BRAF V600 • BRAF V600K
|
Mekinist (trametinib) • Tafinlar (dabrafenib)
Phase 1
GlaxoSmithKline
Completed
Last update posted :
11/17/2017
Initiation :
02/12/2013
Primary completion :
09/04/2015
Completion :
09/04/2015
IL2
|
BRAF V600E • BRAF V600 • BRAF V600K
|
Mekinist (trametinib) • Tafinlar (dabrafenib) • Yervoy (ipilimumab)
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/19/2017
Initiation :
10/01/2014
Primary completion :
02/01/2015
CRP
|
BRAF V600E • BRAF V600 • BRAF V600K
|
Mekinist (trametinib) • Tafinlar (dabrafenib)
Phase 2
GlaxoSmithKline
Completed
Last update posted :
09/27/2017
Initiation :
08/09/2010
Primary completion :
07/01/2011
Completion :
06/01/2016
BRAF
|
BRAF V600E • BRAF V600 • BRAF V600K
|
Tafinlar (dabrafenib)
Phase 2
Yale University
Completed
Last update posted :
03/10/2017
Initiation :
04/01/2013
Primary completion :
06/01/2014
Completion :
06/01/2014
BRAF
|
BRAF V600E • BRAF V600 • BRAF V600K
|
Zelboraf (vemurafenib)
Phase N/A
Genentech, Inc.
Completed
Last update posted :
11/02/2016
Initiation :
12/01/2012
Primary completion :
09/01/2013
Completion :
09/01/2013
BRAF
|
BRAF V600E • BRAF V600 • BRAF V600K • BRAF V600R • BRAF V600D
|
Zelboraf (vemurafenib)